IN THE SPOTLIGHT

Case Report: ALK-rearranged mesenchymal neoplasms with S100 and CD34 co-expression: additional cases with distinct characteristics

Case Report: ALK-rearranged mesenchymal neoplasms with S100 and CD34 co-expression: additional cases with distinct characteristics

Alectinib approved in Italy as adjuvant therapy for NSCLC Alk-positive

Alectinib approved in Italy as adjuvant therapy for NSCLC Alk-positive

Alectinib-Bevacizumab Combo Demonstrates Activity in Treatment-Naïve, ALK-Rearranged, Metastatic NSCLC

Alectinib-Bevacizumab Combo Demonstrates Activity in Treatment-Naïve, ALK-Rearranged, Metastatic NSCLC

Lorlatinib Yields Distinguishing CNS Benefit in ALK-Positive NSCLC

Lorlatinib Yields Distinguishing CNS Benefit in ALK-Positive NSCLC

Pfizer's Lorviqua wins insurance coverage for 1st-line ALK-positive NSCLC in Korea

Pfizer's Lorviqua wins insurance coverage for 1st-line ALK-positive NSCLC in Korea

Exploring First-Line ALK Inhibitors, TKI Sequencing in ALK-Positive NSCLC

Exploring First-Line ALK Inhibitors, TKI Sequencing in ALK-Positive NSCLC

Lorlatinib Yields No Unexpected Toxicities in ALK-Positive NSCLC

Lorlatinib Yields No Unexpected Toxicities in ALK-Positive NSCLC

Oscar Arrieta: Alectinib Plus Bevacizumab as First-Line Treatment in ALK-Rearranged NSCLC

Oscar Arrieta: Alectinib Plus Bevacizumab as First-Line Treatment in ALK-Rearranged NSCLC

Oscar Arrieta: Alectinib Plus Bevacizumab as First-Line Treatment in ALK-Rearranged NSCLC

Oscar Arrieta: Alectinib Plus Bevacizumab as First-Line Treatment in ALK-Rearranged NSCLC

Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial

Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.